Cellectar Biosciences
Cellectar Biosciences, Inc. (Form: 3, Received: 04/18/2017 18:02:05)
FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Swirsky Douglas J

2. Date of Event Requiring Statement (MM/DD/YYYY)
4/10/2017 

3. Issuer Name and Ticker or Trading Symbol

Cellectar Biosciences, Inc. [CLRB]

(Last)        (First)        (Middle)

C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                            _____ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

MADISON, WI 53716       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Remarks:
Exhibit List Exhibit 24 - Power of Attorney
No securities are beneficially owned.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Swirsky Douglas J
C/O CELLECTAR BIOSCIENCES, INC.
3301 AGRICULTURE DRIVE
MADISON, WI 53716
X



Signatures
/s/ Chad Kolean, attorney-in-fact for Douglas J. Swirsky 4/18/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

Exhibit 24

 

CONFIRMING STATEMENT

 

This Statement confirms that the undersigned has authorized and designated Gregory J. Lynch, Michael H. Altman, Joshua B. Erekson, Kelly Teelin, Chad Kolean and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Gregory J. Lynch, Michael H. Altman, Joshua B. Erekson, Kelly Teelin, Chad Kolean and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned’s ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Gregory J. Lynch, Michael H. Altman, Joshua B. Erekson, Kelly Teelin, Chad Kolean and Christina Blakley are not assuming any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

 

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned’s filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

 

Dated: April 18, 2017 Signed: /s/ Douglas J. Swirsky
   
  Print Name: Douglas J. Swirsky